GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Cereno Scientific AB (FRA:4A1) » Definitions » EV-to-EBITDA

Cereno Scientific AB (FRA:4A1) EV-to-EBITDA : -41.50 (As of May. 30, 2025)


View and export this data going back to 2021. Start your Free Trial

What is Cereno Scientific AB EV-to-EBITDA?

EV-to-EBITDA is calculated as enterprise value divided by its EBITDA. As of today, Cereno Scientific AB's enterprise value is €282.18 Mil. Cereno Scientific AB's EBITDA for the trailing twelve months (TTM) ended in Mar. 2025 was €-6.80 Mil. Therefore, Cereno Scientific AB's EV-to-EBITDA for today is -41.50.

The historical rank and industry rank for Cereno Scientific AB's EV-to-EBITDA or its related term are showing as below:

FRA:4A1' s EV-to-EBITDA Range Over the Past 10 Years
Min: -40.05   Med: 0   Max: 0
Current: -40.05

FRA:4A1's EV-to-EBITDA is ranked worse than
100% of 735 companies
in the Drug Manufacturers industry
Industry Median: 13.98 vs FRA:4A1: -40.05

EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.

As of today (2025-05-30), Cereno Scientific AB's stock price is €0.956. Cereno Scientific AB's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2025 was €-0.034. Therefore, Cereno Scientific AB's PE Ratio (TTM) for today is At Loss.

The "classic" EV-to-EBITDA is much better in capturing debt and net cash than the PE Ratio (TTM).


Cereno Scientific AB EV-to-EBITDA Historical Data

The historical data trend for Cereno Scientific AB's EV-to-EBITDA can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Cereno Scientific AB EV-to-EBITDA Chart

Cereno Scientific AB Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
EV-to-EBITDA
Get a 7-Day Free Trial Premium Member Only Premium Member Only -5.70 -30.04 -8.15 -24.02 -22.04

Cereno Scientific AB Quarterly Data
Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25
EV-to-EBITDA Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -19.49 -21.25 -36.51 -22.04 -21.95

Competitive Comparison of Cereno Scientific AB's EV-to-EBITDA

For the Drug Manufacturers - Specialty & Generic subindustry, Cereno Scientific AB's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Cereno Scientific AB's EV-to-EBITDA Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Cereno Scientific AB's EV-to-EBITDA distribution charts can be found below:

* The bar in red indicates where Cereno Scientific AB's EV-to-EBITDA falls into.


;
;

Cereno Scientific AB EV-to-EBITDA Calculation

Cereno Scientific AB's EV-to-EBITDA for today is calculated as:

EV-to-EBITDA=Enterprise Value (Today)/EBITDA (TTM)
=282.180/-6.8
=-41.50

Cereno Scientific AB's current Enterprise Value is €282.18 Mil.
Cereno Scientific AB's EBITDA for the trailing twelve months (TTM) ended in Mar. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was €-6.80 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Cereno Scientific AB  (FRA:4A1) EV-to-EBITDA Explanation

EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.

Cereno Scientific AB's PE Ratio (TTM) for today is calculated as:

PE Ratio (TTM)=Share Price (Today)/Earnings per Share (Diluted) (TTM)
=0.956/-0.034
=At Loss

Cereno Scientific AB's share price for today is €0.956.
Cereno Scientific AB's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was €-0.034.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio (TTM).

Please read Which price ratio outperforms the enterprise multiple?


Cereno Scientific AB EV-to-EBITDA Related Terms

Thank you for viewing the detailed overview of Cereno Scientific AB's EV-to-EBITDA provided by GuruFocus.com. Please click on the following links to see related term pages.


Cereno Scientific AB Business Description

Traded in Other Exchanges
Address
BioVentureHub, Pepparedsleden 1, Molndal, SWE, 431 83
Cereno Scientific AB is developing a pipeline of preventive therapeutics to treat cardiovascular and rare diseases by epigenetic modulation through histone deacetylase inhibition (HDACi). The company's lead program, CS1, is a phase two dual-acting antithrombotic drug aimed at venous thrombosis and stroke prevention for atrial fibrillation. Cereno Scientificalso evaluates the potential of epigenetic modulation for rare diseases related to pulmonary fibrosis, thrombosis, inflammation, and high blood pressure in the pulmonary circulation system.

Cereno Scientific AB Headlines

No Headlines